Vulvovaginal Candidiasis Clinical Trial
Official title:
Comparative Performance of the SavvyCheck Vaginal Yeast Test Versus Culture
The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.
Status | Recruiting |
Enrollment | 1200 |
Est. completion date | August 30, 2026 |
Est. primary completion date | August 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Symptomatic Women Symptomatic women include those women who present with a complaint consistent with symptoms of vaginitis (e.g., increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination). Enrollment will continue at each clinical site until our target number of 216 Reference Method (vaginal Candida yeast culture) positives have been collected. We estimate up to 600 symptomatic women will be enrolled to meet our target. Inclusion Criteria for Symptomatic Women 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Women experiencing vaginal symptoms, including: increased discharge, itching, soreness and irritation, rash on the labia, and genital burning that may worsen during urination 7. Must determine the test is applicable to her based on her symptoms after she has read the outside device labeling (box label) Asymptomatic Women Asymptomatic women include those women who do not present with a complaint consistent with vaginitis. Enrollment will continue at each clinical site until our target number of 170 Reference Method (vaginal Candida yeast culture) negatives have been collected. We estimate up to 320 asymptomatic women will be enrolled to meet our target. Inclusion Criteria for Asymptomatic Women: 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Healthy women appearing for routine care without symptoms of vaginal yeast infection Exclusion Criteria: If any of the following criteria are met, a potential subject will be excluded from the study: 1. Currently menstruating 2. History of any clinical therapies and/or interventions related to gender confirmation (transgender person) 3. Use of any vaginal medication, taken by mouth or vaginally, within the last 7 days 4. Use of any vaginal product within 24 hours, including contraception (cream, gel, or foam), or douching solutions NOTE: Women who currently have an intrauterine device (IUD) placed are eligible to participate |
Country | Name | City | State |
---|---|---|---|
Germany | Landstuhl Regional Medical Center | Landstuhl | |
United States | Womack Army Medical Center | Fort Bragg | North Carolina |
United States | Brooke Army Medical Center | Fort Sam Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Uniformed Services University of the Health Sciences | Savvyon Diagnostics Ltd. |
United States, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result -vs vaginal wet mount microscopy | Calculation of concordance between the results between the lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy | 12 months | |
Other | Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result -vs. PCR and sequencing | Calculation of concordance between the results between the lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing | 12 months | |
Other | Assess concordance between the Reference Method results (vaginal yeast culture) -vs PCR and sequencing | Calculation of concordance between the Reference Method (vaginal yeast culture) results -vs PCR and sequencing | 12 months | |
Primary | Assess sensitivity and specificity between lay user-performed SavvyCheck Vaginal Yeast Test result compared to the Reference Method (vaginal Candida yeast culture) | Calculation of sensitivity and specificity of the lay user-performed SavvyCheck Vaginal Yeast Test as compared to the Reference Method (vaginal Candida yeast culture) | 12 months | |
Secondary | Assess positive and negative predictive values of the lay-user SavvyCheck Vaginal Yeast Test result as compared to the Reference Method (vaginal Candida yeast culture) | Calculation of the positive and negative predictive values of lay user-performed SavvyCheck Vaginal Yeast Test results as compared to the Reference Method (vaginal Candida yeast culture). | 12 months | |
Secondary | Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result and the trained user-performed result. | Calculation of concordance between the lay use-performed and the trained user-performed SavvyCheck Vaginal Yeast test results. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05012852 -
Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis
|
N/A | |
Completed |
NCT02150655 -
Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women
|
Phase 0 | |
Completed |
NCT00755053 -
Comparative Efficacy of Ovule vs Tablet
|
Phase 3 | |
Completed |
NCT02679456 -
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
|
Phase 2 | |
Completed |
NCT02242695 -
Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis
|
Phase 4 | |
Recruiting |
NCT06397248 -
DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
|
||
Completed |
NCT00895453 -
Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
|
N/A | |
Completed |
NCT05327192 -
VVC Sampling Study for Analysis Validation
|
||
Completed |
NCT05399641 -
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
|
Phase 3 | |
Completed |
NCT01806623 -
The Study Of Fluconazole For Vulvovaginal Candidiasis
|
Phase 3 | |
Completed |
NCT05507333 -
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
|
N/A | |
Completed |
NCT01144286 -
Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
|
Phase 2 | |
Completed |
NCT00353561 -
Diabetes Mellitus and Vulvovaginal Candidiasis
|
Phase 3 | |
Recruiting |
NCT05895162 -
Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
|
N/A | |
Not yet recruiting |
NCT06450990 -
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT05908682 -
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
|
||
Completed |
NCT02203942 -
Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis
|
N/A | |
Completed |
NCT01926028 -
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
|
Phase 1/Phase 2 | |
Completed |
NCT00194324 -
Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina
|
Phase 4 | |
Completed |
NCT02866227 -
TOL-463 Phase 2 Study for Vaginitis
|
Phase 2 |